These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32220013)

  • 1. Serum markers alone can define high-risk smouldering multiple myeloma: new insights from the Czech Myeloma Group model.
    Sørrig R
    Br J Haematol; 2020 Jul; 190(2):137-138. PubMed ID: 32220013
    [No Abstract]   [Full Text] [Related]  

  • 2. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model.
    Hájek R; Sandecka V; Špička I; Raab M; Goldschmidt H; Beck S; Minařík J; Pavlíček P; Radocha J; Heindorfer A; Jelínek T; Stejskal L; Brožová L; Ševčíková S; Straub J; Pika T; Pour L; Maisnar V; Seckinger A; Hose D
    Br J Haematol; 2020 Jul; 190(2):189-197. PubMed ID: 32163180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
    Sandecka V; Popkova T; Stork M; Maisnar V; Minarik J; Jungova A; Pavlicek P; Stejskal L; Pospisilova L; Heindorfer A; Obernauerova J; Gregora E; Sykora M; Ullrychova J; Wrobel M; Kessler P; Jelinek T; Kunovszki P; Bathija S; Gros B; Wilbertz S; Cai Q; Lam A; Spicka I
    Blood Cancer J; 2023 Sep; 13(1):153. PubMed ID: 37752128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying current smouldering myeloma risk models to a UK single-centre cohort and clinical features at progression.
    Ainley L; Camilleri M; Chavda SJ; McMillan A; Lee L; Popat R; Sillito F; Yong K
    Br J Haematol; 2022 Mar; 196(6):e63-e66. PubMed ID: 34812509
    [No Abstract]   [Full Text] [Related]  

  • 5. The difficult business of assessing new therapies for smouldering multiple myeloma.
    Zonder JA
    Br J Haematol; 2018 Aug; 182(4):463-464. PubMed ID: 29767407
    [No Abstract]   [Full Text] [Related]  

  • 6. Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma.
    Dalla Palma B; Marchica V; Pedrazzoni M; Accardi F; Notarfranchi L; Goldoni M; De Luca F; Costa F; Storti P; Toscani D; Sammarelli G; Bonomini S; Aversa F; Giuliani N
    Br J Haematol; 2018 Dec; 183(5):812-815. PubMed ID: 29143308
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival in smouldering myeloma and symptomatic myeloma: Is there an emerging Will Rogers phenomenon?
    Chakraborty R
    Eur J Cancer; 2022 Sep; 172():234-236. PubMed ID: 35797760
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk Stratification of Precursors to Multiple Myeloma in 2020.
    Chudasama R; Barth P
    R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.
    Tessier C; Allard T; Boudreault JS; Kaedbey R; Éthier V; Fortin F; Pavic M
    Curr Oncol; 2021 May; 28(3):2029-2039. PubMed ID: 34073289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.
    Soomro MA; Hoffman J; Goodman AM; Sborov DW; Mohyuddin GR
    Br J Haematol; 2022 Jun; 197(6):e86-e88. PubMed ID: 35229286
    [No Abstract]   [Full Text] [Related]  

  • 11. Burning questions about smouldering myeloma.
    DeWeerdt S
    Nature; 2020 Nov; 587(7835):S58-S59. PubMed ID: 33239807
    [No Abstract]   [Full Text] [Related]  

  • 12. Smoldering Myeloma and the Art of War.
    Lonial S; Dhodapkar MV; Rajkumar SV
    J Clin Oncol; 2020 Jul; 38(21):2363-2365. PubMed ID: 32463739
    [No Abstract]   [Full Text] [Related]  

  • 13. Should high risk smoldering myeloma be treated outside a clinical trial: NO.
    Gertz MA; Vaxman I
    Leuk Lymphoma; 2021 Nov; 62(11):2565-2567. PubMed ID: 34261405
    [No Abstract]   [Full Text] [Related]  

  • 14. Early treatment for high-risk smouldering myeloma: has the time come?
    Ludwig H
    Lancet Oncol; 2016 Aug; 17(8):1030-1032. PubMed ID: 27402144
    [No Abstract]   [Full Text] [Related]  

  • 15. Early intervention effective in smouldering multiple myeloma.
    Gourd E
    Lancet Oncol; 2019 Dec; 20(12):e666. PubMed ID: 31679982
    [No Abstract]   [Full Text] [Related]  

  • 16. The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt.
    Mohyuddin GR; Ouchveridze E; Goodman A; Prasad V
    Leuk Lymphoma; 2021 Nov; 62(11):2793-2795. PubMed ID: 34114943
    [No Abstract]   [Full Text] [Related]  

  • 17. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regression of smoldering myeloma with treatment of Gaucher disease.
    Barley K; Parekh A; Salam S; Mendu DR; Shukla RP; Vatti D; Verina D; Stauffer C; Salib C; El Jamal S; Teruya-Feldstein J; Duffield AS; Leshchenko VV; Jagannath S; Balwani M; Parekh S
    Blood Adv; 2024 Apr; 8(7):1634-1638. PubMed ID: 38285963
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Smoldering Myeloma: Problems With Study Design as well as Biological and Clinical Implications.
    Biran N; Vesole DH; Donato ML; Ip A; Kaur G; Goldberg S; Siegel DS
    J Clin Oncol; 2020 Apr; 38(12):1367-1368. PubMed ID: 32160077
    [No Abstract]   [Full Text] [Related]  

  • 20. Smoldering Multiple Myeloma: Who and When to Treat.
    Mateos MV; González-Calle V
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.